| |
De-risk your biological product supply with a seamless technology transfer. With more than 50 new product introductions in the last 12 months across biological modalities, Lonza is an experienced partner for clinical and commercial biological product manufacturing in liquid/lyo vials and prefilled syringes. Discover how. 
|
|
Today’s Big NewsMay 16, 2024 |
| By James Waldron Roche’s incursion into the obesity space seems to be paying off so far based on the first clinical readout since the drugmaker scooped up Carmot Therapeutics for $2.7 billion. |
|
|
|
By Angus Liu The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer, where the CD19 CAR-T will again compete with Gilead Sciences and Novartis drugs. |
By Conor Hale Thermo Fisher Scientific has put forward a DNA-based test that it says can offer much more precise identification of blood and its compatibility. |
By Kevin Dunleavy The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. With 18 of the industry’s top 25 companies achieving year-over-year revenue gains, Q1 came close to matching the final quarter of last year, when 21 of the top 25 companies showed increases. Once again, the dominant players were the sellers of GLP-1 diabetes and obesity drugs. |
|
Wednesday, May 22, 2024 | 10am ET / 7am PT In this webinar, we'll explore how emerging technologies aid Medical Affairs teams in understanding their research's online influence and reaching the right audiences. Topics include analyzing audience engagement, identifying influential opinion leaders, monitoring real-world conversations, and discovering emerging researchers. Register now. 
|
|
By Max Bayer J&J is buying Proteologix for $850 million in cash with more milestone payments available. The deal gives J&J access to a suite of early bispecific antibodies targeting immunology and inflammation conditions. |
By Nick Paul Taylor AstraZeneca is yet to put allegations of unequal pay behind it. Almost three years after AstraZeneca settled claims it underpaid female sales reps, a court has cleared three women to continue trying to build a case against the company. |
By James Waldron Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t got the message yet. |
By Fraiser Kansteiner GSK plans to sell its remaining holding in consumer healthcare spinoff Haleon, the British drugmaker said Thursday. After prior divestments, GSK currently owns about 385 million Haleon shares. |
By James Waldron While AstraZeneca’s globally used COVID-19 vaccine is leaving the scene, the British Big Pharma is hoping it will be taking a fresh therapeutic option to regulators soon. |
By Nick Paul Taylor Lundbeck has learned an unwanted lesson in the value of DTC advertising. After pushback from the FDA forced Rexulti depression ads off the air, Lundbeck reported a flattening of prescriptions that appears to be rebounding now promotion has resumed. |
By Conor Hale The former Fierce Medtech Fierce 15 winner, previously known as AblaCare, has been developing its “ovarian rebalancing” approach that aims to restore a person’s natural ovulation cycle. |
By Fraiser Kansteiner Galapagos has teamed up with the largest blood supply network in the U.S. to help establish decentralized CAR-T production on a national scale. |
By Andrea Park With the FDA’s first approval for a treatment for Rett syndrome now under its belt, Daybue maker Acadia Pharmaceuticals has debuted its latest effort to raise awareness around the rare disease. |
By Ben Adams As the FDA mulls over SpringWorks’ experimental neurofibromatosis type 1 drug mirdametinib during its rolling submission, the biotech isn't wasting time in getting the awareness message about this rare disease out into the world. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 5, 2024 | 2pm ET / 11am PT Delayed diagnosis of autoimmune diseases is common due to subjective symptoms, lack of definitive testing, and gender bias. This can cause worsening symptoms and disease progression, while simultaneously leading to missed research opportunities and reduced revenue for pharma. Join us to learn about key advancements in RWD for helping address these issues. Register now. 
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
